Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|February 7, 2022
Why PSMA imaging is unique from other prostate cancer imaging technologies
Author(s)Urology Times staff
We've never had an imaging agent like this before,” says Leonard S. Marks, MD.
Advertisement
In this video, Leonard S. Marks, MD, gives an overview of the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer. He details how this technology will affect the detection and treatment of patients with this disease and is hopeful of its real-world application in the future. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.
Advertisement
Related to this article
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to VIR-5500 for mCRPC
2
FDA grants 510(k) clearance to OpenFlo urinary catheter
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
5